KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

West Pharmaceutical Services (WST) Other Gross PP&E Adjustments (2016 - 2026)

West Pharmaceutical Services has reported Other Gross PP&E Adjustments over the past 18 years, most recently at $3.1 billion for Q1 2026.

  • Quarterly Other Gross PP&E Adjustments rose 7.26% to $3.1 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.1 billion through Mar 2026, up 7.26% year-over-year, with the annual reading at $3.1 billion for FY2025, 7.81% up from the prior year.
  • Other Gross PP&E Adjustments was $3.1 billion for Q1 2026 at West Pharmaceutical Services, roughly flat from $3.1 billion in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $3.1 billion in Q3 2025 and troughed at $2.1 billion in Q3 2022.
  • The 5-year median for Other Gross PP&E Adjustments is $2.7 billion (2024), against an average of $2.7 billion.
  • Biggest five-year swings in Other Gross PP&E Adjustments: rose 2.81% in 2022 and later increased 16.96% in 2023.
  • Tracing WST's Other Gross PP&E Adjustments over 5 years: stood at $2.3 billion in 2022, then rose by 15.63% to $2.6 billion in 2023, then increased by 9.19% to $2.9 billion in 2024, then rose by 7.81% to $3.1 billion in 2025, then increased by 0.21% to $3.1 billion in 2026.
  • According to Business Quant data, Other Gross PP&E Adjustments over the past three periods came in at $3.1 billion, $3.1 billion, and $3.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.